Resources

This report describes results from a PATH project conducted to better understand the landscape of potential technologies for manufacturing polio vaccines from non-infectious sources, specifically S19, mRNA, and virus-like particle (VLP) platforms.Vaccines manufactured from non-infectious sources are an important tool in the post polio-eradication era given remaining risks of accidental poliovirus release into the environment.Results from the project provide in-depth information about the developability, acceptability and market demand for such next-generation polio vaccines.​ Articulating the relative pros and cons of each platform will help to guide future investment decisions. Key outputs analyzed include the following:The use case for future non-infectious polio vaccinesDevelopability of the three potential non-infectious vaccine platformsThe potential market and associated demand for a next-generation non-infectious polio vaccineDisease containment, including 1) guidelines for novel oral polio vaccines and S19, and 2) environmental and community impacts of accidental exposure under containment or temporary waived conditions (in progress)

This slide provides a snapshot of the Group B Streptococcus (GBS) vaccine technology landscape, in the effort to track the development of GBS vaccine candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the GBS Vaccine Clinical Trial Tracker, which provides publicly available information on clinical trials of GBS vaccine candidates intended for disease prevention.To share any updates or corrections to the snapshot, please contact gbssnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of Group B Streptococcus (GBS) candidate vaccines intended for disease prevention.Sources of information for these trials include clinicaltrials.gov, who.int/clinical-trials-registry-platform, clinicaltrialsregister.eu, chictr.org.cn, and anzctr.org.au.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine clinical trials. This spreadsheet pairs with the GBS Vaccine Snapshot, which provides a summary of the GBS vaccine candidates in development worldwide.To share any updates or corrections to the tracker, please contact gbssnapshot@path.org.

To support the development and introduction of more sensitive rapid diagnostic tests (RDTs) for malaria, PATH and the Institut Pasteur de Dakar partnered to evaluate the performance of three novel LDH-based RDTs developed by Rapigen (Republic of Korea). This study evaluated the clinical performance and usability of three of Rapigen’s BIOCREDIT RDTs among a febrile population in Kédougou, Senegal, comparing them to current tests (the standard HRP2-based RDT and microscopy) and against PCR and quantitative antigen reference assays. The following brief summarizes key results from this evaluation.

In 2017, African leaders made a historic commitment to improving access to lifesaving vaccines across the African continent by endorsing the Addis Declaration on Immunization (ADI). This pledge included a targeted goal to expand domestic investments, ensuring that every African benefits from immunization.The Africa Centers for Disease Control and Prevention (CDC) and the African Union Commission conducted a comprehensive review of the ADI to assess the implementation progress of the ten ADI commitments between 2017 and 2023, highlighting areas of slow advancement and disparities in progress among African Union member states. To corroborate this review, findings from a retrospective study, conducted by PATH’s Center for Advocacy and Policy, in nine African countries on immunization financing between 2017 and 2023, provided additional evidence—especially on the fluctuating trends in government financing for immunization.The following immunization advocacy resources include an overview Africa brief, and country-specific briefs that provide key findings and recommendations from the study and highlight common trends, challenges, and opportunities.